Consistent with the cell line models, the transcriptomic analyses using patient-derived AML samples in TCGA datasets indicated that the mRNA level of CD80 was significantly higher in these FLT3-ITD AML patients compared with the FLT3-WT AML patients. This evidence concerns the gene CD80 and acute myeloid leukemia.